- Home
- AVIR vs XOMA Comparison
AVIR vs XOMA Comparison
Compare AVIR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | XOMA |
|---|---|---|
| Founded | 2012 | 1981 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.0M | 308.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVIR | XOMA |
|---|---|---|
| Price | $4.74 | $24.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 580.2K | 412.4K |
| Earning Date | 04-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | $77.29 |
| Revenue Next Year | N/A | $29.30 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $18.40 |
| 52 Week High | $4.70 | $39.92 |
Technical Indicators
Market Signals| Indicator | AVIR | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 71.86 | 43.68 |
| Support Level | $4.04 | $22.29 |
| Resistance Level | $4.50 | $25.08 |
| Average True Range (ATR) | 0.24 | 1.41 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 93.23 | 37.37 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.